Valuation: Resverlogix Corp.

Market Cap 24.54M 17.52M 15.31M 14.13M 13.02M 1.69B 25.09M 169M 66.41M 826M 65.79M 64.35M 2.84B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 110M 78.75M 68.82M 63.51M 58.54M 7.58B 113M 759M 299M 3.71B 296M 289M 12.79B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.4%
Yield 2024 *
-
Yield 2025 -
1 week 0.09
Extreme 0.09
0.11
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.3
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap.
5/4/26 Option

Chief Financial Officer

300,000 0.0949%
5/4/26 Option

Chief Financial Officer

300,000 0.0949%
3/6/26 Option

Chief Financial Officer

250,000 0.0869%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-25.93%+5.26% 24.54M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.50%-2.36%+33.90%+166.17% 23.36B
Weighted average by Cap. -2.80%-2.36%+39.54%+143.11%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.45M -4.76M -4.39M -4.05M -525M -7.8M -52.53M -20.66M -257M -20.47M -20.02M -885M -7.77M -5.54M -4.84M -4.47M -4.12M -534M -7.94M -53.44M -21.02M -261M -20.82M -20.36M -900M
Net Debt 81.87M 58.44M 51.07M 47.12M 43.44M 5.63B 83.69M 563M 222M 2.76B 219M 215M 9.49B 85.79M 61.23M 53.51M 49.38M 45.52M 5.9B 87.69M 590M 232M 2.89B 230M 225M 9.94B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-07-17 CA$0.1000 0.00% 8,100
26-07-16 CA$0.1000 0.00% 1,900
26-07-15 CA$0.1000 +5.26% 33,558
26-07-14 CA$0.0950 -9.52% 47,615
26-07-13 CA$0.1050 +5.00% 89,125